Edge Therapeutics Enters into Merger Agreement with PDS Biotechnology to Form a Clinical-Stage Cancer Immunotherapy Company
Read More
Edge Therapeutics PDS Biotechnology Proposed Merger Presentation

Corporate Profile

We are a clinical-stage biotechnology company that seeks to discover, develop and commercialize novel therapies capable of transforming treatment paradigms in the management of serious medical conditions.

Read More

Stock Information

EDGE (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$0.40
Change (%) Stock is Down 0.01 (0.00%)
Volume16,326
Data as of January 17, 2019 4:00 p.m. ET
Refresh quote

IR Contact

Gregory Gin
Email: ir@edgetherapeutics.com

More >>

Latest News

November 26, 2018 - Edge Therapeutics Enters into Merger Agreement with PDS Biotechnology to Form Clinical-Stage Cancer Immunotherapy Company
Read More
November 1, 2018 - Edge Therapeutics Reports Third Quarter 2018 Financial Results
Read More
August 1, 2018 - Edge Therapeutics Reports Second Quarter 2018 Financial Results
Read More

More >>

Data provided by Nasdaq. Minimum 15 minutes delayed.

Printer Friendly Version Print PageE-mail this page Email PageRSS RSS FeedsE-mail Alerts Email AlertsView contacts IR Contacts